Media headlines about Immunomedics (NASDAQ:IMMU) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Immunomedics earned a news sentiment score of 0.07 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 47.471188301225 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:
- Ichimoku Cloud Indicator Review for Immunomedics, Inc. (NASDAQ:IMMU): Base Line Touches 23.8616 (hawthorncaller.com)
- Stock Bulletin: Immunomedics Inc (IMMU) (emnnews.com)
- Immunomedics Inc (IMMU): What are the Levels Showing? (baycityobserver.com)
- The Importance And The Opportunity: NovoCure Limited (NVCR), Immunomedics, Inc. (IMMU) (nmsunews.com)
- Should Be Able To Maintain Growth Momentum: Immunomedics, Inc. (IMMU) (nmsunews.com)
Shares of NASDAQ IMMU opened at $24.78 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 14.83 and a current ratio of 14.83. The firm has a market capitalization of $4.80 billion, a price-to-earnings ratio of -24.06 and a beta of 1.79. Immunomedics has a 52-week low of $8.68 and a 52-week high of $27.33.
Immunomedics (NASDAQ:IMMU) last announced its quarterly earnings results on Thursday, August 23rd. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.46). The company had revenue of $0.40 million during the quarter, compared to the consensus estimate of $4.27 million. Immunomedics had a negative net margin of 12,701.21% and a negative return on equity of 124.54%. The business’s revenue was down 33.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.48) earnings per share. equities analysts forecast that Immunomedics will post -1.09 earnings per share for the current year.
Several analysts have recently commented on the stock. BidaskClub upgraded shares of Immunomedics from a “buy” rating to a “strong-buy” rating in a research report on Friday, May 25th. Zacks Investment Research upgraded shares of Immunomedics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 16th. B. Riley raised their price objective on shares of Immunomedics from $53.00 to $55.00 and gave the company a “buy” rating in a research report on Friday, August 24th. Finally, ValuEngine downgraded shares of Immunomedics from a “strong-buy” rating to a “buy” rating in a research report on Monday, June 11th. One analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. Immunomedics presently has a consensus rating of “Buy” and a consensus target price of $32.00.
In related news, Director Venbio Select Advisor Llc purchased 575,000 shares of Immunomedics stock in a transaction on Friday, June 15th. The shares were bought at an average cost of $24.00 per share, for a total transaction of $13,800,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 14.80% of the company’s stock.
Immunomedics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers.
Read More: Trading Strategy Examples and Plans
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.